Product Overview
Pseudotyped VSV-SARS-CoV-2 S-ΔG-Luciferase (Omicron variant, BA.2.86) encodes the antigenomic-sense (or positive-sense) RNA of a replicaton-restricted recombinant vesicular stomatitis virus (rVSV) in which the glycoprotein (G) gene has been replaced with SARS-CoV-2 spike protein (T19I, R21T, Δ24-26, A27S, Δ69-70 V127F, G142D, Δ145, F157S, R158G, Δ211, L212I, V213G, L216F, H245N, A264D, I332V, G339H, K356T, S371F, S373P, S375F, T376A,R403K, D405N, R408S, K417N, N440K, V445H, G446S, N450D, L452W, N460K, S477N, T478K, N481K, Δ483, E484K, F486P, Q493R, Q498R, N501Y, Y505H, E554K, A570V, D614G, P621S, H655Y, 670V, N679K, P681R, N764K, D796Y, S939F, Q954H, N969K, P1143L). Because the infectivity of Pseudotyped VSV-SARS-CoV-2 S-ΔG-Luciferase is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices.The pseudotype VSV particles encode Luciferase together with the VSV nucleocapsid (N), phosphoprotein (P), glycoprotein (G), and large polymerase subunit (L) in their pVSV-ΔG vector. When the VSV pseudovirus infect the target cells, Luciferase expression is proportional to the number of cells that were infected.
COA
Publication 
Loading ......
